Organon relies on the expertise of our employees to produce breakthrough medicines. Through our commitment to women's health care, we have contributed significantly to three areas of vital importance: contraception, fertility and menopause. We have developed some of the most innovative prescription medicines for mental health, anaesthesia, and cardiovascular disease as well. Products that contribute to the health of people and their quality of life.

Our commitment to pursuing therapeutic advances is further reflected in our investment in research and development (R&D). More than 18 percent of annual sales income is devoted to R&D, funding the work of scientists worldwide. Such a sizable investment is necessary given the amount of time and resources involved in new drug development. The entire process from laboratory to pharmacy shelf takes between 10 and 12 years and costs more than Euro 800 million. It is a challenging, high-risk enterprise when you consider that as many as 5,000 compounds are discarded for every one drug that reaches the market. Organon is proud to have a robust pipeline containing many technologically innovative compounds offering enhanced therapeutic efficacy in many areas of specialization.

We would like to invite you to discover more about Organon — our products and our people — by surfing our site and discover with us why health matters.

If any questions remain after reading our website, do not hesitate to contact us.